Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alkermes, Arch, Astex, Beyond Air, Cidara, Cyclo, Diffusion, Forma, KBP, Roche, Santhera.

Responding to COVID-19’s wakeup call as it exposes the risks of relying heavily on foreign biopharma supply chains, the U.S. Department of Health and Human Services (HHS) signed a four-year, $354 million agreement with a team of private industry partners, led by Phlow Corp., to expand U.S. manufacturing of essential medicines at risk of shortage during the pandemic and in future public health emergencies.

LONDON - EMA Director General Guido Rasi has hit out at the lack of coordination in COVID-19 clinical trials, questioning if the huge number of small studies that are running will support regulatory decision-making.

Representing the highest amount ever raised by a public biopharma company on a U.S. exchange, Moderna Inc. priced a $1.34 billion follow-on offering to help fund worldwide manufacturing and distribution of its mRNA-1273 vaccine for COVID-19.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Kempharm, Novartis, Organicell, Theralase, Tolero.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abnova, Adjuvance, Aetion, Be The Match, Cabaletta, Centivax, Cytodyn, Dyne, Genocea, Match, Haliodx, Imcheck, Innovation Pharmaceuticals, Ipsen, Innovent, Merck & Co., Nantkwest, Onxeo, Oragenics, Pharmajet, Primary Peptides, Prellis, Promis, Qingdao Primedicine, Revance, Rising Pharma, Ritter, Sernova, Shionogi, Sophiris, Therapix, Timber, Xenetic.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Agios, Amplyx, Arbutus, Biogen, Covis, Hepion, Lidds, Mezzion, MGB Biopharma.

A quick look back at top stories.